- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Mediators of Inflammation
Volume 2012 (2012), Article ID 260473, 7 pages
IL-17 and IL-22 in Cerebrospinal Fluid and Plasma Are Elevated in Guillain-Barré Syndrome
1Department of Neurology, The First Hospital, Jilin University, Jilin Province, Changchun 130021, China
2Department of Neurology, The Affiliated Hospital of Jiangsu University, Jiangsu Province, Zhenjiang 212001, China
3Department of Neurology, The Affiliated Hospital of Medical College, Qingdao University, Shandong Province, Qingdao 266003, China
4Department of Central Laboratory, The Second Part of the First Hospital, Jilin University, Jilin Province, Changchun 130032, China
Received 10 April 2012; Accepted 4 September 2012
Academic Editor: Sunil Kumar Manna
Copyright © 2012 Shujuan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. A. Hughes and D. R. Cornblath, “Guillain-Barré syndrome,” The Lancet, vol. 366, no. 9497, pp. 1653–1666, 2005.
- V. Cosi and M. Versino, “Guillain-Barré syndrome,” Neurological Sciences, vol. 27, supplement 1, pp. s47–s51, 2006.
- P. A. Van Doorn, L. Ruts, and B. C. Jacobs, “Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome,” The Lancet Neurology, vol. 7, no. 10, pp. 939–950, 2008.
- J. R. Perry, A. Fung, P. Poon, and N. Bayer, “Magnetic resonance imaging of nerve root inflammation in the Guillain-Barre syndrome,” Neuroradiology, vol. 36, no. 2, pp. 139–140, 1994.
- R. A. Hughes, J. C. Raphaël, A. V. Swan, and P. A. van Doorn, “Intravenous immunoglobulin for Guillain-Barré syndrome,” Cochrane Database of Systematic Reviews, no. 1, p. CD002063, 2006.
- J. C. Raphaël, S. Chevret, R. A. Hughes, and D. Annane, “Plasma exchange for Guillain-Barré syndrome,” Cochrane Database of Systematic Reviews, no. 2, p. CD001798, 2002.
- P. Miossec, “IL-17 and Th17 cells in human inflammatory diseases,” Microbes and Infection, vol. 11, no. 5, pp. 625–630, 2009.
- A. L. Gurney, “IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues,” International Immunopharmacology, vol. 4, no. 5, pp. 669–677, 2004.
- S. J. Aujla, Y. R. Chan, M. Zheng et al., “IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia,” Nature Medicine, vol. 14, no. 3, pp. 275–281, 2008.
- Y. Zheng, P. A. Valdez, D. M. Danilenko et al., “Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens,” Nature Medicine, vol. 14, no. 3, pp. 282–289, 2008.
- L. A. Zenewicz and R. A. Flavell, “Recent advances in IL-22 biology,” International Immunology, vol. 23, no. 3, pp. 159–163, 2011.
- D. Matusevicius, P. Kivisäkk, B. He et al., “Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis,” Multiple Sclerosis, vol. 5, no. 2, pp. 101–104, 1999.
- S. A. Metawi, D. Abbas, M. M. Kamal, and M. K. Ibrahim, “Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA,” Clinical Rheumatology, vol. 30, no. 9, pp. 1201–1207, 2011.
- S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003.
- Y. H. Lo, K. Torii, C. Saito, T. Furuhashi, A. Maeda, and A. Morita, “Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy,” Journal of Dermatological Science, vol. 58, no. 3, pp. 225–227, 2010.
- S. Brand, F. Beigel, T. Olszak et al., “IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration,” American Journal of Physiology, vol. 290, no. 4, pp. G827–G838, 2006.
- A. D. Beyeen, M. Z. Adzemovic, J. Öckinger et al., “IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation,” Journal of Immunology, vol. 185, no. 11, pp. 6883–6890, 2010.
- A. K. Asbury and D. R. Cornblath, “Assessment of current diagnostic criteria for Guillain-Barre syndrome,” Annals of Neurology, vol. 27, supplement 1, pp. S21–S24, 1990.
- R. A. C. Hughes, J. M. Newsom-Davis, G. D. Perkin, and J. M. Pierce, “Controlled trial of prednisolone in acute polyneuropathy,” The Lancet, vol. 2, no. 8093, pp. 750–753, 1978.
- Y. Iwakura, H. Ishigame, S. Saijo, and S. Nakae, “Functional specialization of interleukin-17 family members,” Immunity, vol. 34, no. 2, pp. 149–162, 2011.
- K. Wolk, E. Witte, K. Witte, K. Warszawska, and R. Sabat, “Biology of interleukin-22,” Seminars in Immunopathology, vol. 32, no. 1, pp. 17–31, 2010.
- H. Ikeuchi, T. Kuroiwa, N. Hiramatsu et al., “Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine,” Arthritis and Rheumatism, vol. 52, no. 4, pp. 1037–1046, 2005.
- H. L. Zhang, S. Azimullah, X. Y. Zheng, et al., “IFN-γ, deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response,” Journal of Neuroimmunology, vol. 246, no. 1-2, pp. 18–26, 2012.
- Z. Zhang, Z. Y. Zhang, and H. J. Schluesener, “Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects,” Journal of Immunology, vol. 183, no. 5, pp. 3081–3091, 2009.
- L. J. Chi, W. H. Xu, Z. W. Zhang, H. T. Huang, L. M. Zhang, and J. Zhou, “Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy,” Journal of the Peripheral Nervous System, vol. 15, no. 4, pp. 345–356, 2010.
- K. Ghoreschi, A. Laurence, X. P. Yang et al., “Generation of pathogenic TH 17 cells in the absence of TGF-β 2 signalling,” Nature, vol. 467, no. 7318, pp. 967–971, 2010.
- M. Veldhoen, R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger, “TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells,” Immunity, vol. 24, no. 2, pp. 179–189, 2006.
- M. O. Lu and J. Zhu, “The role of cytokines in Guillain-Barré syndrome,” Journal of Neurology, vol. 258, no. 4, pp. 533–548, 2011.
- U. Nussinovitch and Y. Shoenfeld, “The role of gender and organ specific autoimmunity,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A377–A385, 2012.
- H. L. Chiang, R. K. Lyu, M. Y. Tseng et al., “Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders,” Clinica Chimica Acta, vol. 405, no. 1-2, pp. 143–147, 2009.
- B. C. Kieseier, R. Kiefer, R. Gold, B. Hemmer, H. J. Willison, and H. P. Hartung, “Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system,” Muscle and Nerve, vol. 30, no. 2, pp. 131–156, 2004.
- H. Kebir, K. Kreymborg, I. Ifergan et al., “Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation,” Nature Medicine, vol. 13, no. 10, pp. 1173–1175, 2007.
- C. Kamm and U. K. Zettl, “Autoimmune disorders affecting both the central and peripheral nervous system,” Autoimmunity Reviews, vol. 11, no. 3, pp. 196–202, 2012.